Cat. No. 2024
Biological ActivitySelective μ opioid receptor agonist (IC50 values are 5.5 and > 10000 nM for inhibition of 125I-FK 33,824 and 125I-DADLE binding to μ and δ sites respectively). Produces naloxone-reversible analgesia, catalepsy and hyperthermia following central administration in rats in vivo.
(Modifications:Phe-3 = N-methyl-Phe, Pro-4 = C-terminal amide)
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Product Datasheet / Safety Datasheet
References are publications that support the products' biological activity.
Xin et al (1997) Body temperature and analgesic effects of selective mu and kappa opioid receptor agonists microdialyzed into rat brain. J.Pharmacol.Exp.Ther. 281 499. PMID: 9103537.
Meyer and Meyer (1993) Behavioral effects of the μ-opioid peptide agonists DAMGO, DALDA and PL017 on locomotor activities. Pharmacol.Biochem.Behav. 46 391. PMID: 8265694.
Chang et al (1983) Potent morphiceptin analogs: structure activity relationships and morphine-like activities. J.Pharmacol.Exp.Ther. 227 403. PMID: 6313901.
If you know of a relevant reference for PL 017 please let us know.
Citations are publications that use Tocris products.
Do you know of a great paper that uses PL 017 from Tocris? If so please let us know.
View Related Products by Product Action
Keywords: PL 017, supplier, mu, m, opioid, agonists, analgesia, catalepsy, hyperthermia, PL017, potent, selective, Tocris Bioscience, μ Opioid Receptor Agonist products
Find multiple products by catalog number
New Products in this Area
Fluorescent opioid antagonist; fluorescent-derivative of naloxone (Cat. No. 0599)
Follow Tocris on LinkedIn
Visit our LinkedIn page for the latest Tocris news, events and updates.